Xalud Therapeutics
Biotechnology, Health Care, Medical, Neuroscience, Therapeutics
Founded in 1/1/09
New York, New York, United States
For Profit
About Xalud Therapeutics
Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group. The company was established in 2009 and is based in San Francisco, California, United States.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: 11 active products
Financial Information
- Estimated Revenue: Less than $1M
- Total Funding: 42300000 USD
- Last Funding: 30000000 USD (Series C)
- Funding Status: Late Stage Venture
Technology Stack
Xalud Therapeutics actively uses 11 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Medical, Neuroscience, Therapeutics
Headquarters: New York, New York, United States
Employees
- Brendan O'Leary - Chief Operating Officer (LinkedIn)
- Chuck Triano - Chief Financial Officer (LinkedIn)
- Diem Nguyen - Chief Executive Officer (LinkedIn)
- Howard Rutman - Chief Medical Officer (LinkedIn)
- Kristin Murray - Chief Regulatory Officer (LinkedIn)
- Steve Vicik - Chief Technology Officer (LinkedIn)